Publication | Closed Access

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer

Phase Ib StudyBreast OncologyMedicineImmunologyPathologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentImmunotherapyOncologyRadiation OncologyEpcam Antibody Adecatumumab